Eli Lilly stock up 4% on positive data from late-stage trial of Alzheimer’s drug


Eli Lilly & Co.’s stock jumped 8% premarket Wednesday, after the company LLY announced positive results from a late-stage trial of its Alzheimer’s disease treatment donanemab.

The Phase 3 trial showed that donanemab “significantly slowed cognitive and functional decline” in patients with early symptomatic Alzheimer’s disease, and met its primary and all secondary endpoints, or goals.


This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Estee Lauder stock tumbles toward 5-month low after profit miss and lowered sales outlook
Next articleCannabis Watch: Cannabis company offers jobs to laid-off Burger King workers in Michigan, but the overall cannabis employment picture is mixed


Please enter your comment!
Please enter your name here